

RECEIVED
TECH CENTER 1600/2900

03 JUN 18 AM 12:22

PATENT

Customer No. 22,852

Attorney Docket No. 5552.0265-04000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Heinz-Jürgen FRIESEN et al.

Group Art Unit: 1641

Application No.: 09/820,974

Examiner: Christopher L. CHIN

Filed: March 30, 2001

For: SHEET-LIKE DIAGNOSTIC
DEVICECommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450RECEIVED
SEP 10 2003
TECH CENTER 1600/2900RECEIVED
JUN 23 2003
TECH CENTER 1600/2900

Sir:


CONSENT OF ASSIGNEE


Dade Behring Marburg GmbH is the sole Assignee of United States Patent No. 4,861,711, granted August 29, 1989, by a name change from Behring Diagnostics GmbH to Dade Behring Marburg GmbH recorded in the U.S. Patent and Trademark Office on February 17, 1998 at Reel 009197, Frame 0687. Behring Diagnostics GmbH was the sole assignee of the patent by an assignment executed by Behringwerke Aktiengesellschaft recorded in the U.S. Patent and Trademark Office on July 31, 1997 at Reel 008842, Frame 0428. Behringwerke Aktiengesellschaft was the sole assignee of the patent by an assignment executed by Inventors Heinz-Jürgen Friesen, Gerd Grenner, Hans-Erwin Pauly, Helmut Kohl, Klaus Habenstein, and Joseph Stärk and recorded in the U.S. Patent and Trademark Office on December 13, 1985 at Reel 004496, Frame 0645. Dade Behring Marburg GmbH hereby assents to the reissue of

United States patent No. 4,861,711. The evidentiary documents have been reviewed and to the best of Assignee's knowledge and belief, title to the above-identified application is in Assignee.

We hereby declare that we are authorized to execute this document on behalf of Dade Behring Marburg GmbH, that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,


Name: H.-J. Heuser
Position: Vice President
Global Marketing
Hemostasis & IDD
Dated: June 17, 2003


Name: Dr. Bernhard Auerbach
Position: Director Patents and Licenses
Dated: June 17, 2003